Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Jack Khouri, MD, Thapa Bicky, MD, Frederic J. Reu, MD, Christy J. Samaras, DO, Hien D. Liu, MD, Mary Ann Karam, RN, Janice Reed, RN, Beth M. Faiman, PhDCNP, Jason Valent, MD

Blood (2017) 130 (Supplement 1): 1819.

https://doi.org/10.1182/blood.V130.Suppl_1.1819.1819

Published: 2017

Journal Articles

Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models

Yi Hu, Jing Fang, Hua Fang, Chen Li, Shuang Liu, Sarah L. Ondrejka, MD, Zihua Gong, Jaroslaw P. Maciejewski, PhD MD FACP, Frederic J. Reu, MD, Qing Yi, MD PhD, Jianjun Zhao, MD

Blood (2017) 130 (Supplement 1): 1829.

https://doi.org/10.1182/blood.V130.Suppl_1.1829.1829

Published: 2017

Journal Articles

Response-Adapted Therapy for Newly Diagnosed Myeloma

Frederic J. Reu, MD, Tomas Radivoyevitch, PhD, Jason Valent, MD, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt Kalaycio, MD FACP, Hien K. Liu, MD, Christy Samaras, DO, Brian J. Bolwell, MD, Mitchell R. Smith

Blood (2016) 128 (22): 3606.

https://doi.org/10.1182/blood.V128.22.3606.3606

Published: 2016

Journal Articles

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

Hashim Abbas, Lisa A. Rybicki, MS, Frederic J. Reu, MD, Christy Samaras, DO, Mitchell R. Smith, Debbie Hastings, Jason Valent, MD

Blood (2016) 128 (22): 5813.

https://doi.org/10.1182/blood.V128.22.5813.5813

Published: 2016

Journal Articles

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Frederic J. Reu, MD, Jason Valent, MD, Ehsan Malek, MD, Ronald M. Sobecks, MD, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Jamie Elberson, RN, Sherry Fada, Hien K. Liu, MD, Christy Samaras, DO, Mitchell R. Smith, MD PhD

Blood (2015) 126 (23): 4221.

https://doi.org/10.1182/blood.V126.23.4221.4221

Published: 2015

Journal Articles

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Quteba Ebrahem, Reda Z. Mahfouz, MDPhD, Lisa Durkin, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD, Betty K. Hamilton, MD, Aaron T. Gerds, MD MS, Ronald Sobecks, MD, Frederic J. Reu, MD, Eric D. Hsi, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2015) 126 (23): 678.

https://doi.org/10.1182/blood.V126.23.678.678

Published: 2015

Journal Articles

Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)

David S Siegel, Gary Schiller, Kevin Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Frederic J Reu, Jorge Mouro, Michael Sturniolo, Shankar Srinivasan, Anjan Thakurta, Yasir Nagarwala, Nizar J Bahlis, MD

Blood (2015) 126 (23): 1853.

https://doi.org/10.1182/blood.V126.23.1853.1853

Published: 2015

Journal Articles

Response Adapted Induction Therapy for Multiple Myeloma

Jason Valent, MD, Christy Samaras, DO, Debbie Hastings, Beth M Faiman, PhD RN, MSN, CNP, AOCN, Kimberly Hamilton, CNP, Brian J. Bolwell, MD, Janice Reed, RN, Mary Ann Karam, RN, Chad Cummings, MBA, Katherine Tullio, MPH, MS, Mitchell R. Smith, MD PhD, Hien K. Liu, MD, Frederic J Reu

Blood (2015) 126 (23): 3327.

https://doi.org/10.1182/blood.V126.23.3327.3327

Published: 2015

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, PhD, MD, Bart Barlogie, MD PhD, Angela Dispenzieri, MD

Blood (2015) 126 (23): 25.

https://doi.org/10.1182/blood.V126.23.25.25

Published: 2015

Journal Articles

Macrophage Migration Inhibitory Factor Regulates Multiple Myeloma Bone Marrow Homing

Yuhuan Zheng, PhD, Qiang Wang, PhD, Jianfei Qian, PhD, Yi Li, MD, Yong Lu, PhD, Enguang Bi, PhD, Mingjun Zhang, PhD, Tianshu Li, PhD, Maojie Yang, MS, Yu Wu, MD PhD, Frederic J. Reu, MD, Zhen Cai, Qing Yi, MD PhD

Blood (2014) 124 (21): 2015.

https://doi.org/10.1182/blood.V124.21.2015.2015

Published: 2014

Journal Articles

A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma

Sergei Vatolin, PhD, James G Phillips, PhD, Shravya Govindgari, Dale Grabowski, Yvonne Parker, Daniel Lindner, MD PhD, Claudiu Cotta, MD PhD, Frederic J. Reu, MD

Blood (2014) 124 (21): 2085.

https://doi.org/10.1182/blood.V124.21.2085.2085

Published: 2014

Journal Articles

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

David S. Siegel, MD PhD, Jesus G. Berdeja, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Michael (Luhua) Wang, MD, Thomas G. Martin, MD, Ruben Niesvizky, MD, Frederic J. Reu, MD, Sundar Jagannath, MD, Kanya Rajangam, MDPhD, Mei Huang, MS, Ravi Vij, MD

Blood (2014) 124 (21): 2134.

https://doi.org/10.1182/blood.V124.21.2134.2134

Published: 2014

Journal Articles

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Mayur Narkhede, MD, Jason Valent, MD, Chad Cummings, MBA, Katherine Glass, MPH, MS, Debbie Hastings, Beth Faiman, PhD, CNP, Kimberly Hamilton, CNP, Janice Reed, RN, Mary Ann Karam, RN, Matt E. Kalaycio, MD, Brian J. Bolwell, MD, Mitchell R. Smith, MD PhD, Hien K. Duong, MD, Christy Samaras, DO, Frederic J. Reu, MD

Blood (2014) 124 (21): 2620.

https://doi.org/10.1182/blood.V124.21.2620.2620

Published: 2014

Journal Articles

Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

Blood (2014) 124 (21): 978.

https://doi.org/10.1182/blood.V124.21.978.978

Published: 2014

Journal Articles

High Serum Free Kappa Chains Are Frequently Missed By Serum Immunofixation

Surbhi Sidana, MD, Lisa Rybicki, MS, Frederic J. Reu, MD, Thomas Daly, MD

Blood (2014) 124 (21): 5708.

https://doi.org/10.1182/blood.V124.21.5708.5708

Published: 2014

Journal Articles

Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis

Naresh Bumma, MD, Frederic J. Reu, MD, Christy Samaras, DO, Hien K. Duong, MD, Mitchell R. Smith, MD PhD, Jason Valent, MD

Blood (2014) 124 (21): 4753.

https://doi.org/10.1182/blood.V124.21.4753.4753

Published: 2014

Journal Articles

Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis

Surbhi Sidana, MD, Beth Faiman, PhDc, CNP, Paul Elson, ScD, Mitchell R Smith, MD, PhD, Robert M Dean, MD, Jason Valent, M.D., Christy Samaras, DO, Hien K. Duong, MD, Debbie Hastings, Kellie Bruening, Frederic J. Reu, MD

Blood (2013) 122 (21): 1975.

https://doi.org/10.1182/blood.V122.21.1975.1975

Published: 2013

Journal Articles

Lenalidomide Related Diarrhea Correlates With Survival In Multiple Myeloma

Beth Faiman, PhDc, CNP, Surbhi Sidana, MD, Paul Elson, ScD, Kellie Bruening, Hien K. Duong, MD, Robert M Dean, MD, Jason Valent, M.D., Christy Samaras, DO, Debbie Hastings, Mitchell R Smith, MD, PhD, Frederic J. Reu, MD

Blood (2013) 122 (21): 5397.

https://doi.org/10.1182/blood.V122.21.5397.5397

Published: 2013

Journal Articles

Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

Reda Z Mahfouz, MD/PhD, Englehaupt Rickki, Joyce A Juersivich, Kathleen Cooper, RN, MSc, Lisa Durkin, Tomas Radivoyevitch, PhD, Ramon V. Tiu, MD, BS, Frederic J. Reu, MD, Robert M Dean, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Anjali Advani, MD, Eric D. Hsi, MD, Mikkael A Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Yogenthiran Saunthararajah, MD

Blood (2012) 120 (21): 1696.

https://doi.org/10.1182/blood.V120.21.1696.1696

Published: 2012

NARROW

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Daratumumab Is Safe and Highly Effective in AL Amyloidosis

Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models

Response-Adapted Therapy for Newly Diagnosed Myeloma

Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis

A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response

Investigating Efficacy, Safety, and Biomarkers in a Phase 2 Trial of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Following Second-Line Lenalidomide-Based Therapy (Tx) in Relapsed or Refractory Multiple Myeloma (RRMM)

Response Adapted Induction Therapy for Multiple Myeloma

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Macrophage Migration Inhibitory Factor Regulates Multiple Myeloma Bone Marrow Homing

A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma

Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)

Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy

Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

High Serum Free Kappa Chains Are Frequently Missed By Serum Immunofixation

Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis

Neuropathy and Efficacy Of Weekly Subcutaneous Bortezomib In Myeloma and AL Amyloidosis

Lenalidomide Related Diarrhea Correlates With Survival In Multiple Myeloma

Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only